Table 4 Disease‐related factors among patients with rheumatoid arthritis according to the presence of MetS.
Variable | Women with RA | Men with RA | All RA | ||||||
---|---|---|---|---|---|---|---|---|---|
MetS−* (n = 80) | MetS+† (n = 67) | p Value‡ | MetS− (n = 32) | MetS+ (n = 21) | p Value | MetS− (n = 112) | MetS+ (n = 88) | p Value | |
RF positivity, n (%) | 28 (35) | 21 (31.3) | 0.7 | 13 (40.6) | 9 (42.9) | 0.8 | 41 (36.6) | 30 (34.1) | 0.8 |
RA duration, years, mean (SD) | 9.7 (8.6) | 9.4 (10.1) | 0.8 | 8.3 (9.3) | 11.3 (14.8) | 0.4 | 9.3 (8.8) | 9.8 (11.4) | 0.7 |
Extra‐articular manifestations, n (%) | 12 (15) | 16 (23.9) | 0.2 | 6 (18.8) | 4 (19) | 0.9 | 18 (16.1) | 20 (22.7) | 0.3 |
Biological treatment, n (%) | 34 (42.5) | 20 (29.9) | 0.1 | 14 (43.8) | 5 (23.8) | 0.1 | 48 (42.9) | 25 (28.4) | 0.04 |
NSAID, n (%) | 3 (3.8) | 6 (9) | 0.2 | 1 (3.1) | 0 | 0.4 | 4 (3.6) | 6 (6.8) | 0.3 |
Steroids, n (%) | 24 (30.0) | 11 (16.4) | 0.05 | 9 (28.1) | 4 (19) | 0.5 | 33 (29.5) | 15 (17) | 0.04 |
Methotrexate, n (%) | 54 (67.5) | 39 (58.2) | 0.2 | 20 (62.5) | 15 (71.4) | 0.5 | 74 (66.1) | 54 (61.4) | 0.5 |
hs‐CRP, mg/dl, mean (SD) | 0.6 (0.5) | 0.7 (0.7) | 0.3 | 0.9 (0.8) | 0.9 (0.9) | 0.8 | 0.7 (0.6) | 0.8 (0.8) | 0.4 |
ESR, mm/h, mean (SD) | 31.9 (18.6) | 38.1 (20.8) | 0.06 | 27.9 (16.4) | 27.0 (13.5) | 0.8 | 30.8 (18.1) | 35.4 (19.8) | 0.08 |
ESR, erythrocyte sedimentation rate; HDL, high‐density lipoprotein; hs‐CRP, high‐sensitivity C reactive protein; LDL, low‐density lipoprotein; MetS, metabolic syndrome components; NSAID, non‐steroidal anti‐inflammatory drug; RA, rheumatoid arthritis; RF, rheumatoid factor.
Significant (p<0.05) differences are highlighted in bold.
*MetS−: no metabolic syndrome.
†MetS+: metabolic syndrome.
‡Difference between patients with rheumatoid arthritis with and without MetS.